teamLab Planets in Tokyo Unveils Two New Immersive Living Garden Artworks on July 2
teamLab Planets TOKYO in Toyosu, Tokyo is celebrating its third anniversary with an expansion: on July 2, the museum opens a new Garden Area with two interactive garden artworks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005465/en/
teamLab, 2015, Interactive Kinetic Installation, Endless, Sound: Hideaki Takahashi (Photo: Business Wire)
Two gardens will open to the public: a garden where visitors can become one with the flowers, immersing themselves in over 13,000 live orchids that bloom in mid-air; and a moss garden filled with ovoids that shine and resonate when pushed by people or blown by the wind.
Consisting of nine artworks, including four gigantic art spaces and two gardens, teamLab Planets transports visitors to an immersive experience in a museum where they walk through water and a garden where they become one with the flowers.
teamLab Planets Highlight Video: https://youtu.be/-uJTk_mRmUY
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. There are a total of ten artworks, including four massive exhibition spaces and two gardens.
By immersing the entire body with other people in these massive body immersive artworks, the boundary between the body and the artwork dissolves, the boundaries between the self, others, and the world become continuous, and we explore a new relationship without boundaries between ourselves and the world.
Visitors enter the museum barefoot and become completely immersed with other visitors in the vast artwork spaces.
Exhibition Details: planets.teamlab.art/
[Garden Area (2 Garden Artworks)]
Floating Flower Garden; Flowers and I are of the Same Root, the Garden and I are One
teamLab, 2015, Interactive Kinetic Installation, Endless, Sound: Hideaki Takahashi
This floating flower garden consists of a three-dimensional mass of flowers.
The flowers float up above people, and when the people move, the flowers descend again. The artwork space is completely filled with flowers, but as they float up, spaces with people at the center are created. Because of this, people are able to freely wander around the three-dimensional flower mass space. If you encounter other people within the artwork, your space will connect with theirs and become one single space.
Zen gardens are said to have been created as a place for groups of Zen priests to carry out training in order to become one with nature. There is a Chinese Zen kōan (a question or story that is part of Zen priests’ theological training) called, "Nansen’s Flower." A man named Rikukô Taifu, while talking with Nansen, said: "Jô Hoshi says, ‘Heaven and I are of the same root. All things and I are of the same substance.’ How wonderful this is! Nansen, pointing to a flower in the garden said, ‘People these days see this flower as if they were in a dream.’"
In this work, people immerse themselves in flowers, becoming one with the garden. When people become one with the flowers and look at them, the flowers look back. People may truly look at flowers for the first time.
The flowers blooming in the air are epiphytic orchids. Epiphytic plants are extremely common in the orchid family, and epiphytic orchids are able to grow without dirt by absorbing water from the air. The flowers in this artwork are alive, growing, and blooming with each passing day.
Orchids are said to be the last plants to appear on earth. The ground was already covered by other plants, and orchids evolved to live on rocks and trees where other plants could not survive. Orchids adapt and diffuse in a short period of time, and it is said that there are 25,000 to 30,000 kinds of wild species alone. It is believed that there are more types of orchid than any other plant. However, many species are endangered due to the loss of their habitat or overexploitation due to development.
Orchid seeds are as fine as dust, with only immature embryos, no endosperm, and little storage nutrients. In nature, germination of the seed requires symbiosis with a specific fungus, and the symbiotic fungus supplies the nutrients. The seeds have no reserve for germination and cannot sprout themselves, which would seem to contradict the very notion of what a seed is. Seeds should also be a nutrient storehouse for seedlings to germinate, yet the last orchid species to appear on earth has abandoned this aspect. It causes us to wonder why evolution takes certain paths.
Orchids are known to have co-evolved with certain pollen-carrying insects, and it is believed that they continue to evolve rapidly today. The time at which the flowers in the artwork space strengthen in aroma varies according to the time at which these partner insects are active. Because of this, the scent of the artwork space changes each moment between morning, day, and night.
Moss Garden of Resonating Microcosms- Solidified Light Color, Sunrise and Sunset
teamLab, 2021, Interactive Digital Installation, Endless, Sound: Hideaki Takahashi
With sunrise, the ovoids begin to reflect the world around them. When pushed down by a person or blown by the wind, the ovoids fall back and then rise, releasing a resonating tone. The ovoids around it also respond one after another, continuing to resonate with the same tone.
As the sun sets, the ovoids shine by themselves. When an ovoid is pushed by a person or blown by the wind, it falls down and then rises, a sound resonates out, and it emits a light color specific to the sound. The ovoids around it also respond one after another, making the same tone sound, and emitting the same light color that continues to resonate out.
The ovoids begin to flicker slowly when the wind is quiet and people do not push them. Because the ovoid colors are produced by light, it is possible for them to change into 61 different solidified light colors.
[The Following Artworks are Still On View]
Drawing on the Water Surface Created by the Dance of Koi and People - Infinity
teamLab, 2016-2018, Interactive Digital Installation, Endless, Sound: Hideaki Takahashi
Artwork Video: https://youtu.be/qAebQICA-fE
The Infinite Crystal Universe
teamLab, 2018, Interactive Installation of Light Sculpture, LED, Endless, Sound: teamLab
Artwork Video: https://youtu.be/b0BboQnqT_4
Floating in the Falling Universe of Flowers
teamLab, 2016-2018, Interactive Digital Installation, Endless, Sound: Hideaki Takahashi
Expanding Three-Dimensional Existence in Transforming Space - Flattening 3 Colors and 9 Blurred Colors, Free Floating
teamLab, 2018, Interactive Installation, Endless, Sound: Hideaki Takahashi
Artwork Video: https://youtu.be/je04z4596Xc
*Including the above four massive artwork spaces, teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers.
teamLab Planets TOKYO
Term: July 7, 2018 - End of 2022
Venue: teamLab Planets TOKYO (6 Chome-1-16 Toyosu, Koto City, Tokyo)
June: Mon - Fri 10:00 - 18:00 / Sat, Sun, Holidays 09:00 - 19:00
*Last entry 30 minutes before closing
July: Mon - Fri 10:00 - 20:00 / Sat, Sun, Holidays & July 22 - 31 09:00 - 20:00
*Last entry 1 hour before closing
Closed: July 1, July 20
Adults (ages 18 and older): JPY 3,200
University / Trade School Students: JPY 2,500
Middle School / High School Students: JPY 2,000
Children (ages 4 - 12): JPY 300
Infants (ages 3 and younger): Free
Seniors (ages 65 and older): JPY 2,400
Visitors with Disabilities: JPY 1,600
teamLab Planets TOKYO Ticket Store: https://teamlabplanets.dmm.com/en
*Admission and exhibition hours are subject to change. Please check the official website for the latest information.
Official Social Media Pages:
Measures Against the Spread of COVID-19:
Infection prevention measures such as entry restrictions are being implemented. Please check the website for details.
[PLANETS Co., Ltd.]
The managing entity for facilities operations at teamLab Planets TOKYO
Address: Tokyo Nihonbashi Tower 26F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
teamLab (f. 2001) is an international art collective, an interdisciplinary group of various specialists such as artists, programmers, engineers, CG animators, mathematicians and architects whose collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world.
teamLab aims to explore the relationship between the self and the world and new perceptions through art. In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perception of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.
teamLab has been the subject of numerous exhibitions at venues worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, Taipei, and Melbourne among others. The permanent museums teamLab Borderless opened in Odaiba, Tokyo in June 2018, and teamLab Borderless Shanghai in Huangpu District, Shanghai in November 2019. The massive body immersive space teamLab Planets in Toyosu, Tokyo is on view until the end of 2022. The large-scale permanent exhibitionteamLab SuperNaturesoftopened in Macao in June, 2020. teamLab’s annual life-work exhibition, VOLVOteamLab: A Forest Where Gods Live, will be on view in Mifuneyama Rakuen, Takeo Hot Springs, Kyushu starting July 16.
teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development3.8.2021 10:00:00 CEST | Press release
In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. The R&D pipeline in Human Pharma comprises more than 60 new substances and around 100 clinical and pre-clinical projects. This pipeline has the potential to deliver up to 15 medicines for approval by 2025. In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE®). More than 60 million patients worldwide suffer from this disease, approx. half of them from heart failure with preserved ejection fraction (HFpEF). Heart failure with left ventricular preserved ejection fraction occurs when the left ventricle of the heart is unable to fill properly, resulting in less blood being pumped to the body. A recent trial showed a significantly lower risk with empagliflozin of hospi
Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer3.8.2021 09:09:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Gopher Investments (“Gopher”), a 4.97% shareholder in Playtech plc (“Playtech”), is highly disappointed with the Board of Playtech’s decision not to change its recommendation in relation to the offer from Finalto’s management team backed by a consortium led by Barinboim Group (the “Consortium”). Gopher does not believe the supplementary circular contains a full and fair representation of the interaction between Gopher and Playtech since the previous adjournment of the general meeting and therefore wishes to clarify the following chain of events: Gopher responded promptly to an initial information request from the Board, relating to Gopher’s financing and its high confidence of regulatory approval. The Board sought additional information which was commercially conf
SES Networks Expands Partnership With Orange to Enhance Maritime Services3.8.2021 08:50:00 CEST | Press release
Orange maritime customers will now be able to accelerate their digital transformation with higher-capacity satellite connectivity services provided jointly by SES Networks and Orange. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005841/en/ SES Networks Expands Partnership With Orange to Enhance Maritime Services (Photo: Business Wire) With this innovative agreement, Orange will integrate its own global infrastructure with the global network coverage powered by SES Networks’ Skala Global Platform. Together it will enable Orange maritime customers to cost-effectively scale up their bandwidth with seamless, ubiquitous and global services. This will ensure they can implement new technologies onboard that take advantage of IoT and AI, as well as edge and cloud applications. The combination of the Orange secured and digital network infrastructure and SES Networks’ Skala Global Platform -- a next-generation technology platf
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release
RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be
Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release
Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b
The Consortium Welcomes Playtech’s Confirmed Recommendation for Its Binding Agreement to Acquire Finalto and Urges Investors to Vote in Favour at the Playtech Adjourned General Meeting on 18 August 20212.8.2021 19:41:00 CEST | Press release
Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”). Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances”. Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom